Ionis Pharmaceuticals reported positive Phase 3 results for olezarsen in patients with severe hypertriglyceridemia (sHTG). The antisense oligonucleotide significantly reduced fasting triglycerides by up to 72% compared with placebo and lowered acute pancreatitis events by 85%, demonstrating a favorable safety profile with mostly mild injection site reactions. These data support a potential label expansion that could open a multibillion-dollar market targeting patients with elevated triglyceride levels beyond rare inherited conditions.